Blar i forfatter "Halvorsen, Sigrun"

Viser treff 1-7 av 7

    • Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014–2020 

      Ødegaard, Kristina Malene; Lirhus, Sandre Svatun; Melberg, Hans Olav; Hallen, Jonas; Halvorsen, Sigrun (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-10-20)
      Aims - We aimed to study initiation, adherence, and long-term persistence to beta-blockers (BB), renin–angiotensin system inhibitors (RASi), and mineralocorticoid receptor antagonists (MRA) in a nationwide cohort of patients with heart failure (HF).<p> <p>Methods - Patients aged 18–80 years in Norway with a first diagnosis of HF from 2014 until 2020 that survived ≥30 days were identified from the ...

    • BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study 

      Munkhaugen, John; Ruddox, Vidar; Halvorsen, Sigrun; Dammen, Toril; Fagerland, Morten; Hernæs, Kjersti Helene; Vethe, Nils Tore; Prescott, Eva; Jensen, Svend Eggert; Rødevand, Olaf; Jortveit, Jarle; Bendz, Bjørn; Schirmer, Henrik; Kõber, Lars; Botker, Hans Erik; Larsen, Alf Inge; Vikenes, Kjell; Steigen, Terje; Wiseth, Rune; Pedersen, Terje Rolf; Edvardsen, Thor; Otterstad, Jan Erik; Atar, Dan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-25)
      <p><i>Background - </i>Current guidelines on the use of β-blockers in post–acute myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF) are based on studies before the implementation of modern reperfusion and secondary prevention therapies. It remains unknown whether β-blockers will reduce mortality and recurrent MI in contemporary revascularized post-MI patients ...

    • Cost-effectiveness of a rule-out algorithm of acute myocardial infarction in low-risk patients: emergency primary care versus hospital setting 

      Johannessen, Tonje Rambøll; Halvorsen, Sigrun; Atar, Dan; Munkhaugen, John; Nore, Anne Kathrine; Wisløff, Torbjørn; Vallersnes, Odd Martin (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-10-21)
      Aims: Hospital admissions of patients with chest pain considered as low risk for acute coronary syndrome contribute to increased costs and crowding in the emergency departments. This study aims to estimate the cost-effectiveness of assessing these patients in a primary care emergency setting, using the European Society of Cardiology (ESC) 0/1-h algorithm for high-sensitivity cardiac troponin T, ...

    • Design of the GutHeart—targeting gut microbiota to treat heart failure—trial: a Phase II, randomized clinical trial 

      Mayerhofer, Christiane Caroline; Awoyemi, Ayodeji Olawale; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hov, Johannes Espolin Roksund; Aukrust, Pål; Hovland, Anders; Lorenzo, Andrea; Halvorsen, Sigrun; Seljeflot, Ingebjørg; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-08-07)
      <p><i>Aims</i>: Heart failure (HF) is a multifactorial disease. Current treatments target only a fraction of the putative pathophysiological pathways. In patients with HF, reduced cardiac output and congestion cause increased gut wall permeability. It has been suggested that leakage of microbial products is detrimental to the heart, at least partly through activation of systemic inflammatory pathways, ...

    • E. Sverre og medarbeidere svarer 

      Sverre, Elise Christine Bjørkholen; Halvorsen, Sigrun; Løchen, Maja-Lisa; Munkhaugen, John (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-02-20)

    • A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates 

      Ødegaard, Kristina Malene; Lirhus, Sandre Svatun; Melberg, Hans Olav; Hallen, Jonas; Halvorsen, Sigrun (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-03-05)
      Background: The incidence of heart failure (HF) has declined in Europe during the past two decades. However, incidence estimates from registry-based studies may vary, partly because they depend on retrospective searches to exclude previous events. The aim of this study was to assess to what extent diferent lookback periods (LPs) afect temporal trends in incidence, and to identify the minimal ...

    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-28)
      Background - The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).<p> <p>Methods - In a multicentre, prospective randomized open label, blinded ...